AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17311986 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic guidelines
Number of subjects: 0
Study 17311986 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for the Evaluation of Probiotics in Food
Number of subjects: 0
Study 17311986 — intervention group
Group type: EXPERIMENTAL
Intervention: Codex draft on health and nutrition claims
Number of subjects: 0
Study 15249716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 12
Study 11784739 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (muscarinic receptor antagonist)
Number of subjects: 0
Study 11784739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9846709 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) administered subcutaneously for 15 days along with iron and folic acid.
Number of subjects: 20
Study 9846709 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only iron and folic acid.
Number of subjects: 20
Study 7813219 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon (150 micrograms desogestrel + 30 micrograms ethinylestradiol)
Number of subjects: 2
Study 7813219 — intervention group
Group type: EXPERIMENTAL
Intervention: Femovan (75 micrograms gestodene + 30 micrograms ethinylestradiol)
Number of subjects: 2
Study 7813219 — intervention group
Group type: COMPARATOR
Intervention: Both Marvelon and Femovan
Number of subjects: 2
Study 2977177 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 13
Study 2977177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2977177 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide + Naloxone
Number of subjects: 13
Study 2977177 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 13
Study 29294844 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of interpersonal violence (IPV)
Number of subjects: 2000
Study 29294844 — intervention group
Group type: COMPARATOR
Intervention: Prior accident exposure
Number of subjects: 2000
Study 29294844 — intervention group
Group type: COMPARATOR
Intervention: Prior disaster exposure
Number of subjects: 2000
Study 29294844 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 2000
Study 29294844 — intervention group
Group type: COMPARATOR
Intervention: Physical injury to caregiver
Number of subjects: 2000
Study 29294844 — intervention group
Group type: COMPARATOR
Intervention: Concern about others' safety
Number of subjects: 2000
Study 29294844 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 2000
Study 31070146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous benzylpenicillin
Number of subjects: 26
Study 31070146 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Augmentin
Number of subjects: 26
Study 28365000 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided Internet-based CBT
Number of subjects: 94
Study 28365000 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (WL)
Number of subjects: 94
Study 28365000 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 94
Study 25476583 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Mentors (PMs) intervention, which includes information on Medicaid/CHIP eligibility, assistance with application submission, and help maintaining coverage.
Number of subjects: 329
Study 25476583 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving traditional Medicaid/CHIP outreach.
Number of subjects: 329
Study 23949473 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training module (25-minute duration)
Number of subjects: 231
Study 23949473 — intervention group
Group type: COMPARATOR
Intervention: Placebo training module
Number of subjects: 231
Study 16790460 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole given twice a year as part of child health services
Number of subjects: 27995
Study 16790460 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole given annually as part of child health services
Number of subjects: 27995
Study 12491207 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 0
Study 12491207 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ plus azithromycin
Number of subjects: 0
Study 12491207 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ plus fluconazole
Number of subjects: 0
Study 12491207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0
Study 12491207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis against Pneumocystis carinii pneumonia, toxoplasmic encephalitis, and Mycobacterium avium complex bacteremia
Number of subjects: 0
Study 12491207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis against fungal and cytomegalovirus infections
Number of subjects: 0
Study 10026458 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 139
Study 10026458 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles in PTSD patients
Number of subjects: 139
Study 10026458 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles
Number of subjects: 139
Study 8917132 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin selective reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 8917132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2004546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (120 mg per day)
Number of subjects: 173
Study 2004546 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg per day)
Number of subjects: 173
Study 2004546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 173
Study 6319152 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 6319152 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6319152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30565906 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with apathy
Number of subjects: 60
Study 30565906 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without apathy
Number of subjects: 60
Study 30565906 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study 30565906 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy Evaluation Scale (quantitative measure of apathy)
Number of subjects: 60
Study 27084887 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 4pmol/kg/min
Number of subjects: 6
Study 27084887 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 6pmol/kg/min
Number of subjects: 6
Study 27084887 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 8pmol/kg/min
Number of subjects: 6
Study 27084887 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 (all doses)
Number of subjects: 6
Study 24907899 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia patients
Number of subjects: 1440
Study 24907899 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 1440
Study 23822566 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once monthly (400 mg)
Number of subjects: 60
Study 23822566 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once monthly
Number of subjects: 60
Study 21905596 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxiclav (co-amoxiclav) administered twice a day in 12 hour intervals
Number of subjects: 38
Study 19702368 — intervention group
Group type: EXPERIMENTAL
Intervention: Promises manipulated in hypothetical scenarios (Study 1 and Study 2)
Number of subjects: 1382
Study 19702368 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivered inducements manipulated in hypothetical scenarios (Study 1 and Study 2)
Number of subjects: 1382
Study 19702368 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal measurement of promises and delivered inducements (Study 3)
Number of subjects: 1382
Study 17393787 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human-growth hormone (rhGH)
Number of subjects: 40
Study 17393787 — intervention group
Group type: COMPARATOR
Intervention: Control (routine treatment only)
Number of subjects: 40
Study 14763918 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin measurement
Number of subjects: 297
Study 11346729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2%) with epinephrine (1:100,000)
Number of subjects: 17
Study 11346729 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine (3%)
Number of subjects: 17
Study 9134509 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorioamnionitis
Number of subjects: 2
Study 9134509 — intervention group
Group type: COMPARATOR
Intervention: Control group (gestation-matched women with preterm labor)
Number of subjects: 2
Study 8200548 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily omeprazole (20 mg every morning)
Number of subjects: 159
Study 8200548 — intervention group
Group type: COMPARATOR
Intervention: Weekend omeprazole (20 mg on three consecutive days a week)
Number of subjects: 159
Study 8200548 — intervention group
Group type: COMPARATOR
Intervention: Daily ranitidine (150 mg twice daily)
Number of subjects: 159
Study 2828250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline (Bricanyl Retard) 5 mg b.i.d.
Number of subjects: 10
Study 31742760 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding and eating disorders
Number of subjects: 27111
Study 28914707 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes on/10 minutes off
Number of subjects: 24
Study 28914707 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes on/23.5 hours off
Number of subjects: 24
Study 28914707 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 seconds on/8 seconds off
Number of subjects: 24
Study 28914707 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous
Number of subjects: 24
Study 28914707 — intervention group
Group type: COMPARATOR
Intervention: All cycling settings
Number of subjects: 24
Study 28821519 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccinated women
Number of subjects: 15828
Study 28821519 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated cohort
Number of subjects: 15828
Study 26283884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam with oxycodone 1 mg
Number of subjects: 120
Study 26283884 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac with oxycodone 1 mg
Number of subjects: 120
Study 24142738 — intervention group
Group type: EXPERIMENTAL
Intervention: Batifiban alone
Number of subjects: 30
Study 24142738 — intervention group
Group type: EXPERIMENTAL
Intervention: Batifiban coadministered with antithrombin agents
Number of subjects: 30
Study 24142738 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin agents alone (clopidogrel, aspirin, UFH)
Number of subjects: 30
Study 20978529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored modifications to food provision and dining environment over a 15-week period
Number of subjects: 156
Study 20978529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no modifications)
Number of subjects: 156
Study 18460488 — intervention group
Group type: EXPERIMENTAL
Intervention: KGM supplement (1.5 g, tid)
Number of subjects: 7
Study 16570235 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 30
Study 16570235 — intervention group
Group type: COMPARATOR
Intervention: Standardised self-monitoring blood glucose (SMBG) with CGMS
Number of subjects: 30
Study 12643971 — intervention group
Group type: EXPERIMENTAL
Intervention: High responsibility
Number of subjects: 0
Study 12643971 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated responsibility
Number of subjects: 0
Study 12643971 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 0
Study 12643971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood conditions
Number of subjects: 0
Study 11053315 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose solution (CHO trial)
Number of subjects: 13
Study 11053315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Con trial)
Number of subjects: 13
Study 9187991 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose infusion at 250 mL/hr
Number of subjects: 49
Study 9187991 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose infusion at 500 mL/hr
Number of subjects: 49
Study 9187991 — intervention group
Group type: COMPARATOR
Intervention: Control period (no infusion)
Number of subjects: 49
Study 1329491 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone
Number of subjects: 54
Study 1329491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 4062714 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol powder (400 micrograms)
Number of subjects: 40
Study 4062714 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fenoterol powder (200 micrograms)
Number of subjects: 40
Study 31161692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexagliflozin (20 mg)
Number of subjects: 386
Study 31161692 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 386
Study 30048604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Number of subjects: 97
Study 30048604 — intervention group
Group type: COMPARATOR
Intervention: General information on menopause (Control)
Number of subjects: 97
Study 26732120 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized program of muscular strength and endurance with aerobic training
Number of subjects: 0
Study 26732120 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25240757 — intervention group
Group type: EXPERIMENTAL
Intervention: VLP vaccines (H1 or H5) with 5-45 μg of HA/dose
Number of subjects: 280
Study 22450873 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-DMAG (36 mg/m²)
Number of subjects: 67
Study 22450873 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-DMAG (considering between-occasion variability)
Number of subjects: 67
Study 19828561 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin plus pemetrexed (CP; C, 75 mg/m(2) and P, 500 mg/m(2))
Number of subjects: 1725
Study 19828561 — intervention group
Group type: COMPARATOR
Intervention: cisplatin plus gemcitabine (CG; C, 75 mg/m(2) and G, 1250 mg/m(2))
Number of subjects: 1725
Study 19828561 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin plus pemetrexed (CP)
Number of subjects: 1725
Study 19828561 — intervention group
Group type: COMPARATOR
Intervention: cisplatin plus gemcitabine (CG)
Number of subjects: 1725
Study 16969381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnut-enriched diet (40 g/day)
Number of subjects: 15
Study 16969381 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low-fat, low-cholesterol, high-carbohydrate)
Number of subjects: 15
Study 15716196 — intervention group
Group type: EXPERIMENTAL
Intervention: hTRT
Number of subjects: 205
Study 15716196 — intervention group
Group type: EXPERIMENTAL
Intervention: CK20
Number of subjects: 205
Study 15716196 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4
Number of subjects: 205
Study 15716196 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous evaluation of hTRT, CK20, CD4
Number of subjects: 205
Study 15716196 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous evaluation vs Urinary Cytology
Number of subjects: 205
Study 15716196 — intervention group
Group type: COMPARATOR
Intervention: hTRT mRNA vs TRAP
Number of subjects: 205
Study 11902607 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate 0.1%
Number of subjects: 7
Study 11902607 — intervention group
Group type: COMPARATOR
Intervention: Commercial mouthrinses (containing triclosan with fluoride, triclosan with sodium bicarbonate, and herbal components)
Number of subjects: 7
Study 10617168 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/benserazide 100/25 mg
Number of subjects: 32
Study 10617168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8932681 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine succinate 7.5 mg by mouth four times a day (up to nine doses)
Number of subjects: 688
Study 8932681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688
Study 2345835 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined trial design
Number of subjects: 0
Study 2345835 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-academic practitioners as investigators
Number of subjects: 0
Study 2345835 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications in organization and design of the Myocarditis Treatment Trial
Number of subjects: 0
Study 7436066 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TAC (tetracaine 0.5%, adrenaline 1:2,000, cocaine 11.8%)
Number of subjects: 158
Study 7436066 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 158
Study 7436066 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TAC
Number of subjects: 158
Study 29378197 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620 (1 mg, 2 mg, and 4 mg, weekly for 12 weeks)
Number of subjects: 28
Study 29378197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26200467 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDTs followed by ACT
Number of subjects: 15517
Study 26200467 — intervention group
Group type: COMPARATOR
Intervention: Presumptive treatment with ACT
Number of subjects: 15517
Study 26200467 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDTs
Number of subjects: 15517
Study 24153001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nereu programme (8-month intensive family-based multi-component behavioural intervention)
Number of subjects: 100
Study 24153001 — intervention group
Group type: COMPARATOR
Intervention: Counselling (monthly physical health and eating habits session)
Number of subjects: 100
Study 20226412 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT copolymer
Number of subjects: 30
Study 20226412 — intervention group
Group type: COMPARATOR
Intervention: Icodextrin
Number of subjects: 30
Study 18209140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal wash with modified seawater solution (Physiomer) plus standard medication
Number of subjects: 401
Study 16707980 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning products with a mixture of GOS/FOS (4.5 g daily)
Number of subjects: 35
Study 16707980 — intervention group
Group type: COMPARATOR
Intervention: Control weaning products with maltodextrin
Number of subjects: 35
Study 16707980 — intervention group
Group type: COMPARATOR
Intervention: GOS/FOS group vs Control group
Number of subjects: 35
Study 11936740 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication monitors with counseling based on monitor record
Number of subjects: 0
Study 11936740 — intervention group
Group type: COMPARATOR
Intervention: Medication monitors without counseling based on monitor record
Number of subjects: 0
Study 11936740 — intervention group
Group type: COMPARATOR
Intervention: Simple containers for medication
Number of subjects: 0
Study 9829443 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 16
Study 9829443 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 16
Study 9829443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 16
Study 8536044 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritendineum
Number of subjects: 50
Study 8536044 — intervention group
Group type: COMPARATOR
Intervention: Bone grafting of the patellar defect with cancellous bone
Number of subjects: 50
Study 2679856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of potent and weak corticosteroid cream with habit-reversal treatment
Number of subjects: 45
Study 2679856 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid cream alone (control group)
Number of subjects: 45
Study 19897665 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 10117
Study 396650 — intervention group
Group type: EXPERIMENTAL
Intervention: benzilonium bromide (Ulcoban prolongatum)
Number of subjects: 29
Study 396650 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 31814516 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude
Number of subjects: 0
Study 31814516 — intervention group
Group type: COMPARATOR
Intervention: Happiness
Number of subjects: 0
Study 31814516 — intervention group
Group type: COMPARATOR
Intervention: Neutrality
Number of subjects: 0
Study 30954567 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m2 doxorubicin-loaded nanoparticles
Number of subjects: 397
Study 30954567 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/m2 doxorubicin-loaded nanoparticles
Number of subjects: 397
Study 30954567 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 397
Study 29059295 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tandem Traction Bow Appliance (MTTBA)
Number of subjects: 76
Study 29059295 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask (FM)
Number of subjects: 76
Study 29059295 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 76
Study 26943947 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 (200 mg) sprinkled onto applesauce
Number of subjects: 36
Study 26943947 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 beads diluted in Ketocal
Number of subjects: 36
Study 26943947 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 beads diluted in deionized water
Number of subjects: 36
Study 25151339 — intervention group
Group type: EXPERIMENTAL
Intervention: CuZnSOD activity and TAS levels in patients with TD
Number of subjects: 113
Study 25151339 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA levels in patients with TD
Number of subjects: 113
Study 25151339 — intervention group
Group type: EXPERIMENTAL
Intervention: RBANS subscales of Visuospatial/Constructional in patients with TD
Number of subjects: 113
Study 25151339 — intervention group
Group type: EXPERIMENTAL
Intervention: RBANS subscales of attention in patients with TD
Number of subjects: 113